Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Nephrology · Hypertensive nephrosclerosis

Standard Care: Protecting Your Kidneys with Medicine and Lifestyle

At a Glance

Hypertensive nephrosclerosis is managed by setting a safe, individualized blood pressure goal, using kidney-protective medicines when indicated, limiting sodium, staying active, and checking kidney function, potassium, and urine protein after treatment changes.

Managing hypertensive nephrosclerosis is a balancing act. The goal is to lower your blood pressure enough to protect your kidneys and heart without causing side effects like dizziness, falls, or sudden drops in kidney function. Modern treatment has moved toward a more intensive, individualized approach that uses several different “tools” to slow down the progression of the disease [1][2].

Setting the Right Pressure Target

Current international guidelines (KDIGO 2021) suggest a systolic blood pressure (the top number) target of less than 120 mmHg for selected adults with chronic kidney disease [1][3].

However, this target is not a universal rule and comes with important caveats:

  1. Standardized Measurement: This goal applies to blood pressure measured in a standardized way in the clinic—meaning you have rested quietly for five minutes before the reading and the cuff is the correct size. Routine, rushed office readings are often higher than your true average [3][4].
  2. Individual Tolerability: Not everyone should aim for <120 mmHg. If you experience symptomatic postural hypotension (dizziness when standing), are frail, or have other major comorbidities, your doctor will likely set a higher, safer target for you [5][6]. Never adjust your medications yourself just to hit a specific number.

The Pillars of Medication

Treatment is not a rigid algorithm; it is a discussion based on your specific lab results, particularly your albuminuria (protein leak) and eGFR:

1. ACE Inhibitors or ARBs

If you have persistent albuminuria (especially categories A2 or A3), these drugs are highly indicated. They do more than lower systemic blood pressure; they specifically reduce the pressure inside the kidney’s filters [7][8].

  • ACE Inhibitors: Examples include lisinopril and ramipril.
  • ARBs: Examples include losartan and valsartan.
  • The Safety Rule: You should generally never take an ACE inhibitor and an ARB together. Combining them does not provide extra kidney protection but significantly increases the risk of dangerously high potassium levels and sudden kidney failure [9][10].

2. SGLT2 Inhibitors

Originally used for diabetes, medications like dapagliflozin or empagliflozin are increasingly used for kidney protection, depending on your eGFR, albuminuria, and whether you have diabetes or heart failure [11]. In specific clinical trials, they have been shown to reduce the risk of kidney failure [12].

  • What to Expect: It is common to see a small, temporary dip in your eGFR when you first start these. However, a large, persistent, or symptomatic decline requires immediate evaluation [13].
  • Precautions: These drugs increase the risk of genital yeast infections and volume depletion (dehydration). They also carry a rare risk of diabetic ketoacidosis, meaning you must follow strict instructions on when to pause the medication (such as during acute illness or prolonged fasting).

3. Calcium Channel Blockers (CCBs) and Diuretics

If you do not have albuminuria, or if an ACEi/ARB isn’t enough to hit your target, your doctor will likely add:

  • Calcium Channel Blockers (CCBs): Drugs like amlodipine that help relax the blood vessels [14].
  • Diuretics: These help your kidneys remove excess sodium and fluid. Certain classes remain highly effective for blood pressure control even when kidney function is low [15][16].

Lifestyle as Medicine

Medication works best when supported by daily habits:

  • Sodium Reduction: Guidelines generally recommend a target of less than 2,000 mg of sodium per day (which is roughly 5 grams of salt). A renal dietitian can individualize this target. Reducing sodium can improve blood pressure control and reduce protein leakage [17]. Warning: Do not use potassium-based salt substitutes without clinician approval, as CKD and medications already raise your potassium levels.
  • Physical Activity: Aim for regular moderate activity (like brisk walking) based on your clinician’s clearance. Exercise helps keep blood vessels flexible [1][18].

The Treatment Discussion Framework

Priority Action
Step 1 Confirm BP with standardized measurement and home logs [19].
Step 2 Start ACE inhibitor or ARB (if significant protein is in urine) [8].
Step 3 Add SGLT2 inhibitor for kidney protection (if eligible) [11].
Step 4 Add Diuretic or CCB to reach individualized BP goal [20].
Ongoing Monitor potassium and creatinine shortly after any medication change [21].

Common questions in this guide

What blood pressure goal is used for hypertensive nephrosclerosis?
Some adults with chronic kidney disease may be given a standardized systolic target below 120 mmHg. This target is not right for everyone: frailty, dizziness when standing, or other health problems may call for a higher goal. Your clinician should set the target and adjust treatment.
Why are ACE inhibitors or ARBs used when urine contains protein?
ACE inhibitors and ARBs lower blood pressure inside the kidney’s filtering units and can reduce albuminuria, the leakage of protein into urine. They are often considered when albuminuria persists, with kidney function and potassium checked after treatment changes.
Is it safe to take an ACE inhibitor and an ARB at the same time?
These medicines are generally not combined because using both does not add kidney protection and can raise the risk of dangerously high potassium and sudden kidney failure. Do not stop or change either medicine without contacting your prescriber, but ask promptly if both appear on your medication list.
Could an SGLT2 inhibitor help protect my kidneys if I have nephrosclerosis?
An SGLT2 inhibitor may be appropriate for some people based on kidney filtration, urine protein, diabetes status, and heart failure. A small temporary drop in the kidney filtration estimate can occur after starting, but a large, persistent, or symptomatic decline needs prompt medical evaluation. These medicines can also cause dehydration or genital yeast infections and may need to be paused during acute illness or prolonged fasting according to clinician instructions.
How much sodium should I eat to help control blood pressure?
Many guidelines suggest less than 2,000 mg of sodium daily, roughly equal to 5 grams of salt, although a renal dietitian can personalize the goal. Avoid potassium-based salt substitutes unless your clinician approves them because kidney disease and some medicines can raise potassium.
What should be monitored after changing treatment?
Home blood pressure readings and a daily log can help your clinician judge whether treatment is working. Blood tests for potassium and creatinine, along with kidney filtration and urine protein measures, are used to watch for medication effects and disease progression; the timing should be set by your care team.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my target blood pressure number, and was the measurement in the office today done in the 'standardized' way (resting for 5 minutes first)?
  2. 2.Based on my latest urine protein level, should I be on an ACE inhibitor or an ARB, and how high do we plan to increase the dose?
  3. 3.Is an SGLT2 inhibitor a good addition to my current regimen to help protect my kidney function?
  4. 4.Since I am taking an ACE inhibitor/ARB, what are my latest potassium levels, and at what point should we be concerned about them?
  5. 5.Should we adjust my diuretic or blood pressure medication based on my current level of kidney function (eGFR)?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.

    Cheung AK, Chang TI, Cushman WC, et al.

    Kidney international 2021; (99(3)):559-569 doi:10.1016/j.kint.2020.10.026.

    PMID: 33637203
  2. 2

    Hypertension in chronic kidney disease: where do international guidelines converge and diverge?

    Stambolliu E, Stathopoulou E, Bora M, Damianaki A

    Clinical hypertension 2026; (32()):e32 doi:10.5646/ch.2026.32.e32.

    PMID: 42422469
  3. 3

    Management of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice Guideline.

    Tomson CRV, Cheung AK, Mann JFE, et al.

    Annals of internal medicine 2021; (174(9)):1270-1281 doi:10.7326/M21-0834.

    PMID: 34152826
  4. 4

    Comparison of routine office blood pressure measurement versus standardized attended manually activated oscillometric office blood pressure measurement in patients with chronic kidney disease.

    Chellappan A, Kansal K

    Journal of family medicine and primary care 2024; (13(5)):1894-1903 doi:10.4103/jfmpc.jfmpc_1619_23.

    PMID: 38948560
  5. 5

    Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT).

    Rocco MV, Sink KM, Lovato LC, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2018; (71(3)):352-361 doi:10.1053/j.ajkd.2017.08.021.

    PMID: 29162340
  6. 6

    KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD.

    Drawz PE, Beddhu S, Bignall ONR, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2022; (79(3)):311-327 doi:10.1053/j.ajkd.2021.09.013.

    PMID: 35063302
  7. 7

    Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use Among Hypertensive US Adults With Albuminuria.

    Chu CD, Powe NR, McCulloch CE, et al.

    Hypertension (Dallas, Tex. : 1979) 2021; (77(1)):94-102 doi:10.1161/HYPERTENSIONAHA.120.16281.

    PMID: 33190561
  8. 8

    Submaximal Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dosing Among Persons With Proteinuria.

    Chu CD, Powe NR, Estrella MM, et al.

    Mayo Clinic proceedings 2022; (97(11)):2099-2106 doi:10.1016/j.mayocp.2022.07.010.

    PMID: 36210196
  9. 9

    Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.

    Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, et al.

    PLoS medicine 2016; (13(3)):e1001971 doi:10.1371/journal.pmed.1001971.

    PMID: 26954482
  10. 10

    Optimizing renin-angiotensin-aldosterone inhibition in advanced chronic kidney disease: balancing benefits and risks.

    Spencer S, Bhandari S

    Current opinion in nephrology and hypertension 2025; (34(6)):469-476 doi:10.1097/MNH.0000000000001076.

    PMID: 40207744
  11. 11

    Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.

    ,

    Lancet (London, England) 2022; (400(10365)):1788-1801 doi:10.1016/S0140-6736(22)02074-8.

    PMID: 36351458
  12. 12

    EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors.

    Fernández-Fernandez B, Sarafidis P, Soler MJ, Ortiz A

    Clinical kidney journal 2023; (16(8)):1187-1198 doi:10.1093/ckj/sfad082.

    PMID: 37529652
  13. 13

    Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.

    Yau K, Dharia A, Alrowiyti I, Cherney DZI

    Kidney international reports 2022; (7(7)):1463-1476 doi:10.1016/j.ekir.2022.04.094.

    PMID: 35812300
  14. 14

    [New calcium channel blockers for the treatment of hypertension].

    Tamargo J

    Hipertension y riesgo vascular 2017; (34 Suppl 2()):5-8 doi:10.1016/S1889-1837(18)30067-9.

    PMID: 29908667
  15. 15

    Effectiveness of thiazide and thiazide-like diuretics in advanced chronic kidney disease: a systematic review and meta-analysis.

    Teles F, Peçanha de Miranda Coelho JA, Albino RM, et al.

    Renal failure 2023; (45(1)):2163903 doi:10.1080/0886022X.2022.2163903.

    PMID: 36637019
  16. 16

    [Are thiazide diuretics ineffective with a glomerular filtration rate lower than 50 ml/min?]

    Hausberg M

    Innere Medizin (Heidelberg, Germany) 2024; (65(2)):180-184 doi:10.1007/s00108-023-01617-8.

    PMID: 38112725
  17. 17

    Altered dietary salt intake for people with chronic kidney disease.

    McMahon EJ, Campbell KL, Bauer JD, et al.

    The Cochrane database of systematic reviews 2021; (6()):CD010070 doi:10.1002/14651858.CD010070.pub3.

    PMID: 34164803
  18. 18

    Physical activity and nutrition in chronic kidney disease.

    Wang AY, March DS, Burton JO

    Current opinion in clinical nutrition and metabolic care 2023; (26(4)):385-392 doi:10.1097/MCO.0000000000000947.

    PMID: 37265101
  19. 19

    Home Blood Pressure Monitoring: Current Status and New Developments.

    Kario K

    American journal of hypertension 2021; (34(8)):783-794 doi:10.1093/ajh/hpab017.

    PMID: 34431500
  20. 20

    Single-pill combination for treatment of hypertension: Just a matter of practicality or is there a real clinical benefit?

    Coca A, Whelton SP, Camafort M, et al.

    European journal of internal medicine 2024; (126()):16-25 doi:10.1016/j.ejim.2024.04.011.

    PMID: 38653633
  21. 21

    ACE inhibitors and ARBs: Managing potassium and renal function.

    Momoniat T, Ilyas D, Bhandari S

    Cleveland Clinic journal of medicine 2019; (86(9)):601-607 doi:10.3949/ccjm.86a.18024.

    PMID: 31498767

This page explains medicines and lifestyle strategies used for hypertensive nephrosclerosis for informational purposes only and does not replace medical advice. Do not change blood pressure or kidney medicines without discussing it with your healthcare professional.

Get notified when new evidence is published on nephrosclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.